AdAlta Limited
1ADASX$0.00▼ 0.00 (0.14%)
Market Cap
$9.6M
P/E Ratio
—
Div Yield
—
EPS (TTM)
—
Beta
0.19
Currency
AUD
Financial Health
31/ 100
Grade D
Solid liquidity, but growth needs attention
Log in to unlock analysis summary free on one stock of your choice.
Log in to unlock detailed analysis free on one stock of your choice.
| AUD, millions | FY2022 |
|---|---|
| Revenue | 1 |
| Gross Profit | 1 |
| Operating Income | — |
| Net Income | — |
HealthcareBiotechnology
AdAlta Limited, a clinical-stage biotechnology company, develops cellular immunotherapies for the treatment of solid cancers in Australia. The company also commercializes protein therapeutics. In addition, it engages in the development of AD-21, a protein therapeutic for fibrotic diseases, including lung fibrosis and kidney fibrosis in Phase 1 clinical studies; and WD-34, a discovery stage i-body for the treatment and prevention of malaria and related diseases. The company was incorporated in 2006 and is based in Hawthorn East, Australia.
Employees
2
HQ
Hawthorn East, Australia
Website
www.adalta.com.au
Currency
AUD